Clinical Trials List
2021-03-01 - 2027-12-31
Phase III
Recruiting4
Terminated2
ICD-10C64.1
Malignant neoplasm of right kidney, except renal pelvis
ICD-10C64.2
Malignant neoplasm of left kidney, except renal pelvis
ICD-10C64.9
Malignant neoplasm of unspecified kidney, except renal pelvis
ICD-10C7A.093
Malignant carcinoid tumor of the kidney
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9189.0
Malignant neoplasm of kidney, except pelvis
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yen-Hwa Chang Division of Urology
- I-Shen Huang Division of Urology
- Tzu-Ping Lin Division of Urology
- 陳威任 Division of Urology
- Tzu-chun Wei Division of Urology
- 沈書慧 Division of Radiology
- Hsiao-Jen Chung Division of Urology
- Tzu-Hao Huang Division of Urology
- 潘競成 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 裘坤元 Division of Urology
- Cheng-Kuang Yang Division of Urology
- 洪晟鈞 Division of Urology
- 張瓈文 Division of Urology
- Chuan-Shu Chen Division of Urology
- Chia-Yen Lin Division of Urology
- 王樹吉 Division of Urology
- 熊小澐 無
- 盧嘉文 無
- 梅承恩 Division of Urology
- Shian-Shiang Wang Division of Urology
- Cheng-Che Chen Division of Urology
- 林雁婷 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yeong-Shiau Pu Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- FU-JEN HSUEH Division of Hematology & Oncology
- - - Division of Urology
- - - Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- CHUNG-HSIN CHEN Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 楊舜如 Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Yuh-Shyan Tsai Division of Urology
- Jiann-Hui Ou Division of Urology
- Wu-Chou Su Division of Hematology & Oncology
- Che-Yuan Hu Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳彥仰 Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- 林偉雄 Division of Radiology
- 陳彥豪 Division of Hematology & Oncology
- 常景棣 Division of Radiology
- Shau-Hsuan Li Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 郭明濬 Division of General Internal Medicine
- Tai-Jan Chiu Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- PO-HUNG LIN Division of Hematology & Oncology
- 黃亮鋼 Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- Yuan-Cheng Chu 無
- Yung-Chia Kao Division of Hematology & Oncology
- 吳俊德 Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 張鈞弼 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
29 participants
-
Global
1653 participants
